Intra-Osseous Co-Transplant of UCB and hMSC

Intra-osseous Co-transplant of Cord Blood and Mesenchymal Stromal Cells: A Feasibility Study

This clinical trial studies intra-osseous donor umbilical cord blood and mesenchymal stromal cell co-transplant in treating patients with hematologic malignancies. Giving low doses of chemotherapy and total-body irradiation before a co-transplant of donor umbilical cord blood and mesenchymal stromal cells into the bone (intra-osseous) helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil at the time of transplant may stop this from happening.

Study Overview

• Status: Completed
• Conditions: Myelodysplastic Syndromes; Hodgkin Lymphoma; Refractory Hodgkin Lymphoma; Myelofibrosis; Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Chronic Myelogenous Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Non-Hodgkin Lymphoma; Lymphoid Malignancies; Relapsed Non-Hodgkin Lymphoma; Relapsed Chronic Lymphocytic Leukemia
• Intervention / Treatment: Drug: cyclophosphamide; Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Procedure: mesenchymal stem cell transplantation

Detailed Description

PRIMARY OBJECTIVES:

I. To estimate the feasibility of combining intra-osseous umbilical cord blood (UCB) hematopoietic stem cells and human mesenchymal stromal cells (hMSC) following reduced intensity conditioning (RIC).

SECONDARY OBJECTIVES:

I. To estimate the time to engraftment of intra-osseous (IO) UCB transplant combined with hMSC following RIC.

II. To estimate the safety profile of IO UBC transplant combined with hMSC.

OUTLINE:

REDUCED INTENSITY CONDITIONING: Patients receive cyclophosphamide intravenously (IV) over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total body irradiation (TBI) on day -1.

GRAFT-VERSUS-HOST DISEASE (GVHD) PROPHYLAXIS: Patients receive cyclosporine orally (PO) or IV over 2 hours every 12 hours on beginning on days -5 to 100 with taper beginning on day 100 and mycophenolate mofetil IV or PO twice daily (BID) on days -5 to 100.

TRANSPLANT: Patients undergo intra-osseous UCB and hMSC co-transplant on day 0.

After completion of study treatment, patients are followed up at days 28 and 100, and then at 6, 9, and 12 months.

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Early Phase 1

Contacts and Locations

Study Locations

• United States
  • Ohio
    • Cleveland, Ohio, United States, 44106-5065
      • Case Comprehensive Cancer Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients must have one of the following malignancies:

  • Acute myelogenous leukemia (AML): high-risk AML including:

    • Antecedent hematological disease (e.g., myelodysplasia [MDS])
    • Treatment-related leukemia
    • Complete remission (first complete remission [CR1]) with poor-risk cytogenetics or molecular markers (e.g. fms-related tyrosine kinase 3 [Flt 3] mutation, 11q23, del 5, del 7, complex cytogenetics)
    • Second complete remission (CR2) or third complete remission (CR3)

    • Induction failure or first relapse with either

      • ≤ 10% blasts in the marrow and/or
      • ≤ 5% blasts in the peripheral blood

  • Acute lymphoblastic leukemia (ALL)

    • High-risk CR1 including:
    • Poor-risk cytogenetics (e.g., Philadelphia chromosome t(9;22)or 11q23 rearrangements)
    • Presence of minimal disease by flow cytometry after 2 or more cycles of chemotherapy
    • No complete remission (CR) within 4 weeks of initial treatment
    • Induction failure

    • CR2 or CR3 with either:

      • ≤ 10% blasts in the marrow and/or
      • ≤ 5% blasts in the peripheral blood
  • Myelodysplastic syndromes (MDS), Intermediate-1 (INT-1), intermediate-2 (INT-2) or high Revised International Prognostic Scoring System (IPSS-R) score that has failed at least 1 first line therapy

  • Myelofibrosis (MF):

    • Intermediate-2 or high risk by Dynamic International Prognostic Scoring System (DIPSS)-plus
    • Monosomal karyotype
    • Presence of inv(3)/i(17q) abnormalities
    • Other unfavorable karyotype OR leukocytes ≥40 X 10^9/L AND
    • Circulating blasts ≤ 9%

  • Relapsed or refractory lymphoid malignancies (including non-Hodgkin lymphoma, Hodgkin lymphoma and chronic lymphocytic leukemia) meeting the following criteria:

    • Disease status: stable disease, partial remission or 2nd and 3rd complete remission

  • Chronic myelogenous leukemia (CML) in second chronic phase after accelerated or blast crisis; blast crisis defined as:

    • Blast count ≥ 20% in the peripheral blood or bone marrow
    • Large foci of blasts on bone marrow
    • Presence of extra-medullary blastic infiltrate (myeloid sarcoma or chloroma)
  • Recipients of prior autologous or allogeneic transplant are eligible, as long as at least 3 months have passed since the transplant, and the patient fulfills other eligibility criteria
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤2
  • Candidates for reduced intensity conditioning regimens
  • Patients who do not have HLA-matched (defined as matched in HLA A, B, C, and DRB1) related or unrelated donors, those who elect to undergo UCB even if they have a MRD or MUD, or patients who require a UCB either for emergency indications such as primary graft failure.

  • Cord Blood Units available through NMDP with the following minimal criteria:

    • HLA Match: 4/6 or better match (HLA A, B, DRB1)
    • Cell dose: Minimum of 2.0x107TNC/kg pre thaw
  • Concurrent therapy for extramedullary leukemia or central nervous system (CNS) lymphoma: concurrent therapy or prophylaxis for testicular leukemia, CNS leukemia, and CNS lymphoma including standard intrathecal chemotherapy and/or radiation therapy will be allowed as clinically indicated; such treatment may continue until the planned course is completed; subjects must be in CNS remission at the time of protocol enrollment if there is a history of CNS involvement
  • Subjects must have a back-up umbilical cord on the registry in addition to the umbilical cord being used in this study
  • Subjects must have the ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

• Patients with inadequate Organ Function as defined by:

  • Creatinine clearance < 30 ml/min
  • Bilirubin ≥ 2 x institutional upper limit of normal
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) ≥ 2 x institutional upper limit of normal
  • Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≥ 2 x institutional upper limit of normal
  • Corrected diffusing capacity of the lung for carbon monoxide (DLCOcorr) < 40% normal
• Left ventricular ejection fraction < 35%
• Patients with uncontrolled inter-current illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant or breastfeeding women are excluded from this study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Treatment (intra-osseous UCB with hMSC co-transplant); REDUCED INTENSITY CONDITIONING (RIC): Flu/Cy/TBI: Patients receive cyclophosphamide IV over 2 hours on day -6 and fludarabine phosphate IV on days -6 to -2 and undergo total-body irradiation on day -1. Flu/Mel: Patients receive fludarabine daily on days -5 to -2, a single dose of melphalan on day -2, and ATG on day -3 and day-2. GVHD PROPHYLAXIS: Patients receive cyclosporine PO or IV over 2 hours every 12 hours on beginning on days -5 to 100 with taper beginning on day 100 and mycophenolate mofetil IV or PO BID on days -5 to 100. TRANSPLANT: Patients undergo a co-transplantation of an intra-osseous umbilical cord blood transplantation and a mesenchymal stem cell transplantation on day 0.

Drug: cyclophosphamide; All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6; Other Names: Cytoxan; Endoxan; CPM; CTX; Endoxana; Drug: fludarabine phosphate; Given by IV during prep at 40mg/m2 for 5 days; Other Names: 2-F-ara-AMP; Beneflur; Fludara; Radiation: total-body irradiation; Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1; Other Names: TBI; Drug: cyclosporine; Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100; Other Names: ciclosporin; cyclosporin; cyclosporin A; CYSP; Sandimmune; Drug: mycophenolate mofetil; Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated.; Other Names: Cellcept; MMF; Procedure: umbilical cord blood transplantation; Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant.; Other Names: UCB transplantation; cord blood transplantation; transplantation, umbilical cord blood; Procedure: mesenchymal stem cell transplantation; The total dosage of hMSC will be 2x10^6cells/kg (+/-20%).; Other Names: hMSC transplantation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients with BM cellularity failure: Measure of feasibility	Primary graft failure is defined by <10% BM cellularity in bone marrow biopsies. Failure in more than 30% of patients will indicate unfeasibility of treatment	42 days after transplant
Number of patients with ANC failure without evidence of disease: Measure of feasibility	Primary graft failure is defined by <500 ANC cell/ul in bone marrow biopsies. Failure in more than 30% of patients will indicate unfeasibility of treatment	42 days after transplant
Number of patients with hematopoietic recovery without evidence of donor umbilical cord blood engraftment: Measure of feasibility	Primary graft failure is defined by hematopoietic recovery with <10% donor cell chimerism. Failure in more than 30% of patients will indicate unfeasibility of treatment	42 days after transplant
Number of patients with hematopoietic recovery without evidence of donor umbilical cord blood engraftment: Measure of feasibility	Primary graft failure is defined by hematopoietic recovery with <40% donor cell chimerism. Failure in more than 30% of patients will indicate unfeasibility of treatment	100 days after transplant

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of toxicities assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0	Descriptive statistics will be used.	Up to 12 months
Rate of neutrophil recovery	The rate of neutrophil recovery and median time of recovery will be estimated using the methods of Kaplan and Meier.	Up to 12 months
Rate of platelet recovery	The rate of platelet recovery and median time of recovery will be estimated using the methods of Kaplan and Meier.	Up to 12 months
Median time of neutrophil recovery	The median time of neutrophil recovery will be estimated using the methods of Kaplan and Meier.	Up to 12 months
Median time of platelet recovery	The median time of platelet recovery will be estimated using the methods of Kaplan and Meier.	Up to 12 months

Collaborators and Investigators

• Sponsor: Case Comprehensive Cancer Center
• Collaborators: National Cancer Institute (NCI)

Study record dates

Study Major Dates

• Study Start (Actual): July 22, 2015
• Primary Completion (Actual): December 19, 2019
• Study Completion (Actual): February 7, 2020

Study Registration Dates

• First Submitted: July 2, 2014
• First Submitted That Met QC Criteria: July 3, 2014
• First Posted (Estimate): July 4, 2014

Study Record Updates

• Last Update Posted (Actual): December 4, 2020
• Last Update Submitted That Met QC Criteria: December 3, 2020
• Last Verified: December 1, 2020

More Information

Terms related to this study

• Keywords: Cancer; Cyclophosphamide; feasibility; MMF; Mycophenolate Mofetil; GVHD; Fludarabine; Cyclosporine; G-CSF; Total Body Irradiation; DMSO; Human Mesenchymal Stromal Cells; hMSC; Dimethyl Sulfoxide; Granulocyte- Colony Stimulating Factor
• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Bone Marrow Diseases; Hematologic Diseases; Myeloproliferative Disorders; Leukemia, B-Cell; Lymphoma; Myelodysplastic Syndromes; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Hodgkin Disease; Lymphoma, Non-Hodgkin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Antirheumatic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Dermatologic Agents; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antifungal Agents; Antitubercular Agents; Antibiotics, Antitubercular; Calcineurin Inhibitors; Cyclophosphamide; Fludarabine; Fludarabine phosphate; Mycophenolic Acid; Cyclosporine; Cyclosporins
• Other Study ID Numbers: CASE1Z14 (Other Identifier: Case Comprehensive Cancer Center); P30CA043703 (U.S. NIH Grant/Contract); NCI-2014-01316 (Registry Identifier: CTRP (Clinical Trial Reporting Program))

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No